Clin2
NCT07877051Possibly a fitRecruiting

Vapor treatment for heavy menstrual bleeding

Uterine Hemorrhage

Part of Women’s health & pregnancy clinical trials.

This trial tests a new heat-based vapor treatment that removes the lining of the uterus to reduce or stop heavy menstrual bleeding. It may offer an option for women who have not found relief from hormonal treatments and want a non-hormonal approach.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
43 people
Ages
30 years to 55 years
Study type
Interventional

Who can take part

  • You are a woman between 30 and 55 years old
  • You have heavy menstrual bleeding diagnosed as abnormal uterine bleeding
  • You are still having periods (premenopausal) and do not plan to become pregnant
  • You do not want to use hormonal treatments, or hormonal treatments have not worked for you
  • You have had a normal endometrial biopsy and a negative PAP test
  • You have not had a prior uterine ablation or certain uterine surgeries
  • Your uterine cavity length measures between 4 and 6 cm
  • You are not pregnant or breastfeeding and are at least 1 year after childbirth
  • You are not currently using vaginal rings, hormonal IUDs, or oral contraceptives during the study
  • You have no active pelvic or urinary infections and no history of certain uterine abnormalities or cancers

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07169214Recruiting· Phase 1
Study of BT-114143 injection for heavy menstrual bleeding

This trial tests an investigational medication called BT-114143 for people with heavy menstrual bleeding (abnormal uterine bleeding). The goal is to see if it is safe and effective in reducing blood loss during periods.

Beijing, Beijing Municipality
NCT07195305Recruiting
Treating adenomyosis bleeding with heat or artery blocking

This study compares two treatments for heavy bleeding caused by adenomyosis: a procedure that uses heat to remove the inner lining of the uterus (endometrial ablation) and a procedure that blocks blood flow to the uterus (uterine artery embolization). If you have been diagnosed with adenomyosis and have tried medication without success, this trial may help decide which treatment is best for you.

Bordeaux
NCT07529587Not yet recruiting
Comparing two treatments for heavy bleeding due to extra uterine blood vessels

This study compares two treatments for heavy bleeding caused by enhanced myometrial vascularity (extra blood vessels in the womb muscle). One option is a keyhole surgery to clip blood vessels, and the other is inserting a Mirena coil (a hormonal IUD). Joining may help you find which treatment works best for your condition.

NCT05856838Recruiting
Endometrial ablation for heavy periods when medicines don’t work

This study looks at an outpatient procedure that removes part of the uterine lining to reduce very heavy menstrual bleeding. It may help you if birth control or medicines haven’t worked (or you can’t take them) and your uterus tests come back normal.

Ghent, East Flanders
NCT07206342Not yet recruiting
Comparing two treatments for bleeding after miscarriage

This study compares two ways of stopping bleeding after a miscarriage. You would either get a gel to block the bleeding or get the gel plus a small suction procedure. The goal is to see if just using the gel works as well as the combined method, which could mean a simpler treatment.

Bordeaux
NCT07326722Recruiting
Study of tAN device for heavy menstrual bleeding

This study tests whether a small nerve stimulation device (tAN) worn on the ear can help reduce heavy menstrual bleeding. You will use the device during your periods and track your bleeding with provided products and an app.

Boston, Massachusetts

Hear when a new Uterine Hemorrhage trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.